53 results about "Contrast-induced nephropathy" patented technology

The invention discloses an acute aortic syndrome early warning method, system and device and a storage medium, and belongs to the technical field of medical image processing. The method comprises the steps that an aorta CT image is acquired and preprocessed; generating a CTA image by using the cascade generative adversarial network model; and carrying out key information feature extraction on the CTA image by using a deep learning classification model DenseNet, and outputting an aortic syndrome classification result. According to the method, the high-quality CTA image can be generated without using a contrast agent, the risk possibly generated by contrast agent examination of a patient is reduced, and the method is particularly suitable for patients with renal function impairment or contrast agent allergy; compared with the prior art, an economical and efficient alternative scheme is provided, dependence on traditional CTA examination equipment and professionals is reduced, meanwhile, the accuracy rate and the timeliness rate of early warning of the acute aortic syndrome can be effectively increased, and remarkable clinical application value and social benefits are achieved.

The invention discloses a highly inert Gd-DOTA-based contrast agent with a hydrophobic side chain as well as a preparation method and application of the highly inert Gd-DOTA-based contrast agent, and two novel Gd-DOTA-based contrast agents Gd-L1 and Gd-L2 are successfully developed by respectively connecting hydrophobic 3-phenyl propylamine and 3, 3-diphenyl propylamine to Gd-DOTABA. The two novel Gd-DOTA-based contrast agents remarkably improve the chemical inertness of the complex, the dissociation half-life period of the complex in a 1 M HCl solution at 37 DEG C is about 5 times that of Gd-DOTA, and a powerful guarantee is provided for clinical safety; the MRI (Magnetic Resonance Imaging) performance of the liver in a mouse shows that Gd-L1 is equivalent to commercially available Gd-BOPTA and is suitable for imaging of a liver and gall system; after the Gd-L2 is combined with the human serum albumin, the longitudinal relaxation rate is obviously increased (r1 = 14.8 mM <-1 > s <-1 >, 1.4 T, 37 DEG C), the blood elimination half-life period in a rabbit model is about 18 minutes, and the Gd-L2 is suitable for vascular MRI (Magnetic Resonance Imaging). The two contrast agents avoid the spleen residual problem, the organ accumulation possibility is reduced, and a safer and more efficient MRI diagnostic tool is provided for clinic.

The invention discloses a blood brain barrier water extraction rate imaging method and system based on artery marking and speed selection. By marking spinning of water molecules in artery blood and selectively detecting signals of residual marked blood which does not enter brain tissues in vein blood vessels, quantitative evaluation of blood-brain barrier water permeability is realized. According to the method, the neck artery blood flow is magnetized and overturned by adopting pseudo-continuous artery spin labeling, a speed selection module based on Fourier transform is applied in an acquisition stage to eliminate interference of brain tissue signals, pure vein labeling signals are obtained, and rapid and accurate measurement of water extraction fraction and permeability-surface area volume is realized. In addition, the signal-to-noise ratio and robustness are effectively improved by adopting dual suppression pulses of background tissues and blood. The method does not need an exogenous contrast agent, is non-invasive, short in scanning time and accurate and stable in measurement result, and has important clinical application value for early diagnosis of brain diseases and assessment of pathological changes of the blood brain barrier.

The invention relates to the technical field of massage devices, in particular to an intelligent massage device based on CT iodine contrast agent extravasation degree, which comprises a massage base, the massage base is provided with a mounting cavity, and a lifting assembly is mounted at the bottom of the massage base; the first clamping massage assembly and the second clamping massage assembly are installed in the installation cavity through adjusting assemblies respectively, and the first clamping massage assembly and the second clamping massage assembly are oppositely arranged; and the detection assembly is mounted at the top of the mounting cavity and is electrically connected with a control assembly. The method is beneficial to promoting absorption and backflow of exudate of the CT iodine contrast agent, and the risk of complications is reduced.

The invention relates to a contrast-agent-free angiography generation system and method based on mask guidance, a parameter optimization device is used for performing parameter optimization on a conversion device by utilizing a loss function capable of highlighting a contrast agent shadow, and the capability of capturing complex image details of the conversion device is improved. Then, the Gaussian noise image is fused into a contrast-agent-free computed tomography image through a conversion device, computed tomography angiography is obtained through a fusion mode of feature sampling and gradual denoising, and it is guaranteed that the obtained computed tomography angiography has enough consistency and sense of reality; and the sharpness and fidelity of the generated vascular structure are improved.

The invention discloses a novel bismuth-based chelate CT contrast agent and a preparation method and application thereof. The synthesis method comprises the following steps: reacting 2, 6-pyridine dimethyl carbinol with thionyl chloride to obtain 2, 6-bis (chloromethyl) pyridine; the preparation method comprises the following steps: carrying out a heating reaction on 2-(4-methylphenyl)-1, 2, 4-triazine-2-ketone, N, N ', N'-tri (p-toluenesulfonyl) diethylenetriamine and an inorganic base in a solvent, and carrying out concentrated sulfuric acid deprotection to obtain an intermediate pyclen; the preparation method comprises the following steps: heating and reacting pyrene and halogenated carboxylic ester in a polar organic solvent under an alkaline condition, and hydrolyzing to obtain a ligand product; and heating and chelating the ligand product and a bismuth agent to prepare the target bismuth-based chelate. Laboratory large-scale preparation of the small-molecule bismuth-based chelate CT contrast agent is achieved, and the prepared nonionic contrast agent has low osmotic pressure, high stability, high water solubility and good biological safety and is used for CT imaging of digestion, urinary and circulatory systems.

The invention discloses a contrast agent for enhancing an ELCA volume reduction effect, belongs to the field of medical reagents, and particularly relates to a contrast agent, which comprises a heparin-based compound and a contrast agent, the heparin-based compound comprises heparin, and the content of the heparin-based compound in the contrast agent is 2-64 [mu] g / mL. The contrast agent comprises at least one of iopromide and iodixanol. The heparin-based compound further comprises a heparin derivative, the heparin derivative is prepared by oxidizing heparin and then reacting with a derivating agent, and the derivating agent comprises L-alanyl-L-proline methyl ester hydrochloride. The contrast agent provided by the invention can be combined with ELCA for use, enhances the volume reduction effect of ELCA, has a good ablation effect on vascular plaques, and has high shock wave pressure when acting with excimer laser.

The invention relates to the technical field of traditional Chinese medicine compositions and preparations, in particular to a traditional Chinese medicine composition for preventing and treating contrast agent acute kidney injury, a preparation and application. The traditional Chinese medicine composition is prepared from 10 g of radix scutellariae, 15 g of poria peel, 9 g of pericarpium arecae, 9 g of pericarpium citri reticulatae, 9 g of cortex mori, 9 g of ginger peel and 10 g of rhizoma atractylodis macrocephalae. The treatment principle of clearing away heat and toxic materials, dispersing blood stasis, tonifying spleen, clearing damp and promoting diuresis is determined on the basis of contrast agent acute kidney injury caused after contrast agent injection. The traditional Chinese medicine composition has the effects of ascending lucidity and descending turbid, invigorating spleen and replenishing qi, and transporting and transforming water dampness; the effects of clearing away heat and toxic materials, regulating qi-flowing for strengthening spleen and inducing diuresis for The traditional Chinese medicine composition disclosed by the invention is precise and appropriate in compatibility, clear in curative effect and good in patient compliance on contrast agent acute kidney injury which is differentiated as spleen and kidney qi deficiency and blood stasis in traditional Chinese medicine, and the medicine can be stopped after contrast agent radiography is performed for 24 hours; clinical experiments show that the traditional Chinese medicine composition for preventing and treating the contrast agent acute kidney injury is obviously superior to a control group in a traditional Chinese medicine treatment group and has statistical significance (P is less than 0.05).

A quantitative, ultrashort time to echo, contrast-enhanced magnetic resonance imaging technique is provided. The technique can be used to accurately measure contrast agent concentration in the blood, to provide clear, high-definition angiograms, and to measure absolute quantities of cerebral blood volume on a voxel-by-voxel basis.

The invention discloses a nuclear magnetic resonance imaging contrast agent GH-Gd as well as a preparation method and application thereof, and belongs to the multidisciplinary crossing fields of material science, kidney pathology, medical imaging and the like. The structure of the contrast agent GH-Gd is shown in the following formula, and the preparation method of the contrast agent GH-Gd comprises the following steps: adding a compound H-DOTA, GGT-1 and cesium carbonate into anhydrous acetonitrile, and carrying out heating reflux reaction to obtain a compound GH-DOTA; and carrying out chelation reaction on the compound GH-DOTA and gadolinium chloride to obtain the nuclear magnetic resonance imaging contrast agent GH-Gd. The contrast agent GH-Gd is formed by chelating a ligand GH-DOTA with Gd < 3 + >, the contrast agent sequentially plays three functions of kidney integration glomerular filtration, GGT and MPO programmed activated kidney enrichment and enzymatic hydrolysis kidney clearance, and the content and dynamic distribution information of GGT and MPO can be obtained while kidney injury is avoided. # imgabs0 #

The invention discloses a novel nuclear magnetic resonance contrast agent Gd-DOTA-PP for targeting citrullinated histone to achieve neutrophil extracellular trap net imaging and a preparation method and application thereof.The method comprises the steps that citrullinated histone targeting polypeptide PP and ligand molecules DOTA-NHS are combined, and a compound DOTA-PP is obtained; and then gadolinium (Gd) ions are introduced into the DOTA-PP through a coordination reaction, and the novel contrast agent Gd-DOTA-PP is prepared. The contrast agent can be selectively combined with an important marker, namely citrullinated histone, of neutrophil extracellular trapping nets (NETs), and T1 weighted imaging signals of a target area are remarkably enhanced. The preparation method is simple and convenient to operate, the preparation process is highly controllable, and the obtained contrast agent has excellent biocompatibility and targeting characteristic. The accurate targeting ability of the probe enables the influence signal of the probe in NETs enrichment areas such as tumor early metastasis, tumor infiltration lymph nodes and the like to be obviously enhanced, a powerful tool is provided for tumor diagnosis, especially accurate diagnosis of the early metastasis, and the probe has important clinical application value.

This invention discloses a method and system for adjusting and optimizing CT contrast-enhanced scanning parameters, comprising: acquiring the patient's physiological characteristic parameters and injection parameters, and calculating the contrast agent concentration at the target site at different times based on the physiological characteristic parameters and injection parameters, generating a time-density curve. The enhancement coefficient corresponding to the current peak voltage of the X-ray tube is determined using the CT contrast-enhanced curve, and the time-enhanced value curve of the current target site is determined by combining the time-density curve. The peak enhancement value is determined based on the scanning time window and the time-enhanced value curve, and the peak enhancement value is compared with the enhancement target. If the peak enhancement value does not meet the enhancement target, the injection parameters or scanning parameters are adjusted, and the peak enhancement value is recalculated and compared with the enhancement target. This process continues until the peak enhancement value meets the enhancement target. This method can automatically search and decide on the optimal CT contrast-enhanced scanning scheme in reverse, solving the problem of unsatisfactory CT scan results.

This invention provides high sensitivity 19 A fluorine-containing molecule suitable as an F-MRI contrast agent, and a material containing the fluorine-containing molecule as an active ingredient. 19 We provide F-MRI contrast agents. [Solution] A peptide comprising two or more amino acids linked by peptide bonds, wherein the peptide contains a fluorine-containing alkyl group and an organic radical within the same amino acid residue; the peptide according to the above, wherein the fluorine-containing alkyl group is a perfluoroalkyl group having 1 to 6 carbon atoms; the peptide according to the above, wherein the fluorine-containing alkyl group is a trifluoromethyl group or a nonafluoro-tert-butyl group; the peptide according to the above, wherein the organic radical is an N-oxyl radical: A pharmaceutical composition containing any of the above peptides; and a pharmaceutical composition containing any of the above peptides as an active ingredient. 19 F-MRI contrast agent.

Method for determining a measurement start time (ts) for an imaging measurement using a medical imaging system (1) as a function of a time course of concentration values ​​(KD1, ..., KD21) of a contrast agent (CM) in a monitoring area (UB) of an examination object (P) with the following steps: - Recording the concentration values ​​(KD1, ..., KD21) of a current concentration of the contrast agent (CM) in the monitoring area (UB) at various successive recording times (t1, ..., t9), - Determining a current examination-specific enhancement model curve (CM) of a contrast agent enhancement and depletion based on a time course of the concentration values ​​(KD1, ..., KD21) and based on a population-averaged enhancement model curve and / or population-averaged contrast agent impulse response function, - Determination of the measurement start time (ts) based on the examination-specific enhancement model curve (CM).

The invention provides an anterior segment transmission interference microscopic imaging device, method and system, and relates to the technical field of medical optical imaging and ophthalmic diagnosis. The single-frame imaging field of view is not less than 2mm * 1mm and is larger than that of a common clinical confocal microscope and a corneal endothelial mirror, so that the statistical reliability and the lesion detection rate can be improved; through a transmission interference mechanism, corneal nerves, epithelial cells and crystalline lens fine structures can be displayed in a high contrast manner, and the method is particularly suitable for low-scattering transparent tissues; a common-path optical structure is adopted, a reference arm or a high-speed scanning unit is not needed, and the system is small in size, low in cost and good in stability; in the examination process, contact with the ocular surface or introduction of a contrast agent is not needed, and discomfort and risks possibly caused by traditional contact type or intrusive type examination are avoided; the method can be used for corneal nerve evaluation, endothelial disease screening, crystalline lens microstructure observation and preoperative / postoperative follow-up visit.

The application discloses a contrast agent for enhancing the effect of ELCA volume reduction, and belongs to the field of medical reagents, and particularly relates to a contrast agent which comprises a heparin-based compound and a contrast agent, wherein the heparin-based compound comprises heparin, and the content of the heparin-based compound in the contrast agent is 2-64 mu g / mL. The contrast agent comprises at least one of iopromide and iodixanol. The heparin-based compound further comprises a heparin derivative, and the heparin derivative is prepared by subjecting heparin to oxidation and then to reaction with a derivatizing agent. The derivatizing agent comprises L-alanyl-L-proline methyl ester hydrochloride. The application is a contrast agent which can be combined with ELCA, enhances the effect of ELCA volume reduction, has a good effect on blood vessel plaque erosion, and has high shock wave pressure when combined with excimer laser.

A method of determining microvasculature function of a vessel inspection region, the method including: obtaining angiography images of a vessel tree in the vessel inspection region, the angiography images captured over a sampling time window during which a contrast agent has been injected into the vessel tree, and applying the angiography images to a segmentation model configured to generate segmented images of the vessel tree; providing the segmented images to a contrast intensity model and, performing, by the contrast intensity model, a contrast intensity extraction on each of the segmented images to generate a contrast intensity profile of the vessel tree over the sampling time window; providing the contrast intensity profile to a microvasculature health model configured to determine a health of the microvasculature within the vessel tree based on the contrast intensity profile; and determining, using the microvasculature health model, a microvasculature health of microvasculature of the vessel tree.

The utility model belongs to the CT enhancement scanning auxiliary device field especially, and it is more particularly to a urinary system abdominal compression enhancement CT scanning pressurization restraint device. The technical includes the restraint band, the restraint band front side inner wall is provided with the pressurization piece, and the pressurization piece is oval structure, and the restraint band front side outer wall is provided with the adjusting assembly for driving pressurization piece left and right movement. The utility model discloses through the cooperation of restraint band and pressurization piece, is convenient for when scanning and places pressurization piece in patient abdominal side bilateral sacroiliac joint level, delays contrast agent excretion, makes contrast agent temporarily in ureter renal pelvis calyx, renal pelvis calyx expansion, and then utilizes post-processing technology to make contrast agent and lesion show good contrast, thereby benefit the position of judging stone and the relationship with renal pelvis, calyx, ensure the accurate detection and evaluation of kidney stone, also convenient for adjusting the position of pressurization piece according to different patients during use, make the stability and accuracy of scanning result higher while making the applicability higher.

The application discloses a novel bismuth-based chelate CT contrast agent and a preparation method and application thereof. The synthesis method comprises the following steps: 2,6-pyridine dimethyl alcohol is reacted with chlorosulfoxide to obtain 2,6-bis(chloromethyl)pyridine; the 2,6-bis(chloromethyl)pyridine is reacted with N,N',N''-tris(p-tolylsulfonyl)divinyltriamine and an inorganic base in a solvent and is heated, is deprotected by concentrated sulfuric acid to obtain an intermediate pyclen; the pyclen is heated and reacted with a halogenated carboxylic acid ester under alkaline conditions in a polar organic solvent, is hydrolyzed to obtain a ligand product; and the ligand product is heated and chelated with a bismuth agent to obtain the target bismuth-based chelate. The application realizes the laboratory scale preparation of the small-molecule bismuth-based chelate CT contrast agent, and a non-ionic contrast agent is prepared, which has low osmotic pressure, high stability, high water solubility and good biological safety and is used for CT imaging of the digestive system, the urinary system and the circulatory system.

The invention discloses a system, a method, equipment and a medium for generating diffusion from craniocerebral CT to craniocerebral CTA under self-adaptive characterization guidance, and belongs to the technical field of medical image processing and artificial intelligence. The system comprises an adaptive representation extraction module used for extracting a depth feature vector representing a blood vessel and an anatomical structure from an input non-enhanced CT image; the conditional potential diffusion model is used for executing a de-noising diffusion process in a potential space by fusing U-Net of a cross attention mechanism under the condition of the feature vector to generate target feature representation; and the image reconstruction module is used for decoding and reconstructing the potential features into a synthetic CTA image. According to the method, the diffusion generation process is guided through the self-adaptively extracted anatomical priori depth, high-quality and high-anatomical-consistency three-dimensional craniocerebral CTA image synthesis without an iodine contrast agent is realized, and the defects of dependence on the contrast agent, inaccurate blood vessel reduction and poor three-dimensional continuity in the prior art are effectively overcome.

The utility model discloses an enhanced CT (Computed Tomography) examination contrast agent exosmosis real-time detection device, which effectively achieves the purpose of detecting the contrast agent exosmosis phenomenon, and comprises a first protective belt, a detachable second protective belt is arranged in the first protective belt, a connecting belt is arranged between the first protective belt and the second protective belt, and the connecting belt is connected with the first protective belt. The left side and the right side of the connecting belt are respectively connected with an expansion cloth bag used for adjusting wearing tightness, two pressure sensors are arranged on the lower side of the first protective belt, the right side of the first protective belt is fixedly connected with an alarm mechanism, and the lower side of the second protective belt is detachably connected with an application mechanism. The device is simple in structure, ingenious in conception and easy and convenient to operate, the wearing tightness of the device can be effectively adjusted, medical staff can conveniently and rapidly release swelling pressure of a venous access, the function of relieving an affected part in time is added, and an alarm can be given to the exosmosis phenomenon in time.

The invention discloses a system for evaluating coronary artery stenosis through a photon CT low-dose low-concentration contrast agent scheme, and belongs to the field of medical images. The invention discloses a system for evaluating coronary artery stenosis by using a photon CT low-dose low-concentration contrast agent scheme. The system comprises a multi-energy spectrum data acquisition unit, a data preprocessing unit, an image generation unit, an image segmentation unit, a plaque analysis unit and a stenosis detection unit. The problems that in existing coronary artery CT examination, the radiation dosage is high, the contrast agent dosage is large, and the diagnosis process highly depends on physician experience, so that efficiency is low, and subjectivity is high are solved, the photon counting CT detector and optimized low-dosage scanning parameters are adopted, the deep learning algorithm and the multi-material decomposition technology are combined, and the CT examination efficiency is improved. High-quality coronary artery imaging and accurate stenosis evaluation under the conditions of low dosage and low concentration of contrast agents are realized, radiation exposure and contrast agent related risks of patients are remarkably reduced, and accuracy and reliability of coronary artery stenosis detection and plaque component analysis are improved.

The invention provides a contrast-agent-free coronary CTA image generation and diagnostic analysis method and system. The method comprises the steps that a paired data set of a CT image and a real coronary CTA image is plain scanned according to clinical routine; performing data preprocessing on the paired data set to generate an image pair trained by an adaptive model; constructing a corresponding deep learning model based on the image pair, and processing the to-be-processed clinical plain-scan CT image by using the deep learning model to output a corresponding contrast-agent-free coronary artery CTA image; and carrying out image segmentation on the contrast-agent-free coronary CTA image by using a pre-trained segmentation model, and carrying out automatic analysis based on an image segmentation result and the contrast-agent-free coronary CTA image so as to output a corresponding quantitative diagnosis result. According to the method, the contrast-agent-free coronary artery CTA image is directly generated from the clinical conventional plain-scan CT image through the deep learning algorithm, risks such as contrast agent allergy and kidney injury are thoroughly eliminated, and the applicable crowd is expanded.

The present invention relates to a method for measuring glomerular filtration rate (GFR) ex vivo in a subject that has been administered a contrast agent and that has been subjected to computed tomography (CT) or magnetic resonance imaging (MRI) including an excretion phase, a plain scan phase, an arterial phase, and a renal parenchyma phase or a portal vein phase, the method includes the step of calculating contrast agent clearance from CT or MRI data using manual, automated or semi-automated segmentation software, thereby obtaining a measured GFR.

The invention discloses a computed tomography (CT) arteriovenous synchronous imaging method based on dopamine-polyethylene glycol modified hafnium oxide nanoparticles. By systematically optimizing synthesis of the oleylamine ligand modified hafnium oxide nanoparticles and a DA-PEG one-step ligand exchange strategy, the DA-PEG-HfO2 nanoparticles with the hydrodynamic particle size of 10-80 nm can be prepared in a controlled manner. According to the technical scheme, the in-vivo metabolic behavior is remarkably improved while the uniform particle size and good dispersity are kept, liver and spleen uptake and rapid kidney clearing are avoided, and a long-circulation imaging window is achieved. The blood imaging time window of the prepared nanoparticles reaches 1-5 hours, and after single intravenous injection, the contrast enhancement signal lasts gt in the blood vessel; the spatial resolution is superior to 0.15 mm after 120 minutes, and synchronous development of arteries and veins is realized for the first time without multi-stage scanning. The method is simple and convenient in synthesis, capable of realizing gram-level synthesis, high in metal content, good in water solubility, long in blood circulation time and excellent in stability and biological safety, and a new scheme is provided for development of a high-performance CT contrast agent.

This invention discloses a method and device for monitoring contrast agent extravasation, belonging to the field of medical device technology. The method involves dividing the contrast agent injection area into a proximal and distal needle region by identifying the center coordinates of the injection area; projecting a plurality of laser lines onto the proximal and distal needle regions based on the center coordinates; monitoring the deformation difference of the laser lines in the proximal needle region and the intensity ratio of the laser lines in the proximal and distal needle regions based on the laser lines during injection; determining the presence of contrast agent extravasation risk and issuing an alarm command when the deformation difference is not less than a preset deformation threshold and the intensity ratio is not greater than a preset intensity threshold. Therefore, this invention effectively solves the problems of high misdiagnosis rate and low real-time performance in existing technologies.

We report a chelator platform based on diazapyridinophane macrocycles as contrast agents to improve Magnetic Resonance Imaging. Lead compounds identified, [Mn(TE-1)]+ and [Mn(TE-4)], have good relaxivity and kinetic inertness in vivo. Spectrophotometric titrations and in vitro Zn challenge studies of [Mn(TE-4)] showed kinetic inertness with a rate of dissociation of 6.8 x 10-4 s-1, while [Mn(TE-1)]+ has a slower dissociation rate of 1.0 x 10-4 s-1 and a relaxivity of 3.6 mM -1 s-1 measured at 1.4 T magnetic field and 33 ºC. These Mn complexes were investigated by employing the 52Mn radioisotope, a positron emission tomography (PET) radiotracer, to probe kinetic inertness and stability in vivo. The Mn complexes of TE-1 and TE-4 exhibit different behavior in in vivo MRI studies given their different lipophilicity: [Mn(TE-4)] shows contrast enhancement in the kidney and bladder, indicating renal clearance, while the lipophilicity of [Mn(TE-1)]+ promotes a mixed biliary-renal excretion.

This application relates to the field of medical image recognition, and particularly to a system for identifying calcified nodule lesion regions in coronary angiography. The system includes: a coronary angiography image acquisition module that acquires pre-contrast key-frame images and post-contrast key-frame images; a first coronary angiography image analysis module that analyzes the gray-scale distribution and gray-scale change conditions of pixel points in the pre-contrast key-frame images and the post-contrast key-frame images to obtain a set of suspected calcification points; a second coronary angiography image analysis module that combines the distance distribution of elements in the set of suspected calcification points to the edge to obtain a contrast coefficient; obtains the relative displacement of each pixel point through the difference characteristics of the gray-scale distribution between adjacent pixel points in the post-contrast key-frame images, and filters to obtain a suspected calcification distance; a calcified nodule lesion region image recognition module that obtains a cardiac motion fluctuation coefficient and identifies the calcified lesion regions in coronary angiography. This application aims to enhance the recognition ability of tiny calcified lesion regions.

The application relates to a treatment device and method for iodine contrast agent residual waste, and relates to the technical field of medical waste treatment.The device comprises a pretreatment assembly, a degradation assembly and a separation assembly.The pretreatment assembly is used for collecting and pretreating the iodine contrast agent residual waste, the degradation assembly is used for degrading the pretreated waste, and the separation assembly is used for separating the degradation product.The pretreatment assembly, the degradation assembly and the separation assembly are combined to realize the collection and treatment of the iodine contrast agent residual waste, improve the treatment efficiency of the iodine contrast agent residual waste, and reduce the probability of directly discharging the iodine contrast agent residual waste to pollute the environment.

The invention discloses an iodine contrast agent adverse reaction risk prediction method and system for tumor patients, and relates to the technical field of medical data processing and risk prediction. According to the technical key points, the method comprises the following steps of: constructing a tumor patient exclusive multi-dimensional time sequence data set, preprocessing data, constructing a tumor patient exclusive risk factor system, constructing a pharmacological perception drug embedding layer, constructing a multi-scale self-adaptive time sequence feature extraction core module, and coupling and modulating a tumor pathological state and a time sequence risk. Performing multi-feature fusion and risk prediction model training verification, risk prediction and interpretability clinical decision support and clinical iterative optimization of the model; by constructing a multi-dimensional data set, time sequence modes of different anti-tumor drugs in different short, medium and long risk periods are dynamically captured, and the specific pathological state of a tumor patient is used as a modulation factor to non-linearly amplify or weaken the risk intensity of a corresponding time window, so that the accuracy and clinical credibility of risk prediction are improved.